19.86 +0.01 (0.05%)
After hours: 4:27PM EDT
|Bid||19.80 x 1100|
|Ask||19.87 x 3000|
|Day's Range||19.80 - 19.96|
|52 Week Range||17.42 - 23.03|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||33.11|
|Forward Dividend & Yield||0.35 (1.75%)|
|1y Target Est||22.38|
BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
BARCELONA, Spain, July 4, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is used to treat primary immunodeficiencies.
BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line. Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.
BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.
Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...
- About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.
- The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.
BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]